podcast
details
.com
Share
源于细胞BioInsid的个人播客
今天3分钟我们来聊聊同济双靶点CAR-T攻克TP53淋巴瘤
Listen
Description
同济医院创新双靶点CAR-T疗法,让TP53突变淋巴瘤患者5年生存率达70%,改写“最难治”历史,为全球数万患者带来新生希望。
前往小宇宙评论区与主播互动
podcast
details
Print
Share
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
Check it
Made by
Alex Barredo
. Send your feedback to
alex@barredo.es
.